PMID: 18728823Aug 30, 2008Paper

Rasagiline in treatment of Parkinson's disease.

Neuropsychiatric Disease and Treatment
Lakshmi Nayak, Claire Henchcliffe

Abstract

Rasagiline (N-propargyl-1 (R)-aminoindan) is a novel propargylamine, irreversible, selective monoamine oxidase inhibitor for treatment of Parkinson's disease (PD), a progressive condition associated with degeneration of dopaminergic neurons in the substantia nigra. Rasagiline inhibits striatal dopamine metabolism, thereby providing relief from motor symptoms of PD. It may be dosed once daily and, unlike selegiline, it is metabolized to non-amphetamine compounds. In a large clinical trial, rasagiline has proved effective, safe, and well tolerated in early PD as monotherapy. In two phase III clinical trials in advanced PD with motor fluctuations, rasagiline as an adjunct to levodopa significantly decreases "off" time. In animal models of PD, data supports a neuroprotective effect of rasagiline, and its active metabolite aminoindan. Analysis of delayed-start clinical trial suggests the potential for disease modification, and further trials are examining this effect.

References

Feb 1, 1991·Journal of Clinical Psychopharmacology·B Blackwell
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Feb 28, 1970·Nature·G G CollinsM B Youdim
Apr 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·A M O'CarrollK F Tipton
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·M B Youdim
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E C HirschW C Olanow
Oct 18, 2000·JAMA : the Journal of the American Medical Association·C M Tanner
Jan 12, 2001·Clinical Neuropharmacology·J L MontastrucM Lapeyre-Mestre
Dec 21, 2002·Archives of Neurology·UNKNOWN Parkinson Study Group
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Jul 11, 2003·Parkinsonism & Related Disorders·Katherine H FialaBala V Manyam
Dec 17, 2003·Archives of Neurology·Clifford W Shults
Apr 21, 2004·Archives of Neurology·UNKNOWN Parkinson Study Group
May 4, 2004·Parkinsonism & Related Disorders·Keiko KamakuraKazuo Motoyoshi
May 18, 2004·Experimental Neurology·F BlandiniG Nappi
Jul 29, 2004·Current Medicinal Chemistry·P RiedererG Laux
Aug 10, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Matthew B SternC Warren Olanow
Oct 13, 2004·Neurology·Moussa B H Youdim, Peter F Riederer
Nov 20, 2004·The Psychiatric Clinics of North America·Edward C Lauterbach
Dec 2, 2004·Journal of Neuroscience Research·Moussa B H YoudimTamar Amit
Apr 27, 2005·Brain Research. Brain Research Reviews·Silvia MandelMoussa B H Youdim
May 10, 2006·Neurology·C G GoetzUNKNOWN Parkinson Study Group TEMPO and PRESTO Investigators
Jul 11, 2006·Journal of the Neurological Sciences·L ElmerUNKNOWN PRESTO Investigators
Jul 21, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·J Antonelle deMarcaidaUNKNOWN PRESTO Tyramine Substudy Investigators and Coordinators
Mar 21, 2007·Neurology·Anthony E Lang
Jul 11, 2007·Current Opinion in Neurology·Albert Y Hung, Michael A Schwarzschild

❮ Previous
Next ❯

Citations

Sep 27, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Vibha PrasadAaron Voigt
Aug 13, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·William K GrayRichard W Walker
Feb 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Mark R Cookson
Feb 6, 2018·Biomedical Reports·Alireza AbdanipourReza Nejatbakhsh
Oct 9, 2015·The Cochrane Database of Systematic Reviews·Roy G ElbersGert Kwakkel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.